• Habitual miscarriage: what you should do and what you should not do (Review)
To content

Habitual miscarriage: what you should do and what you should not do (Review)

HEALTH OF WOMAN. 2018.1(127): 9–13; doi 10.15574/HW.2018.127.9

Zhabchenko I. A.
SI «Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine», Kiev

The article presents an overview of domestic and foreign publications on pregravid preparation and early pregnancy in women with a history of habitual miscarriage (HM).
Modern terminology is presented, questions about the causes of this pathology are considered and ways of its overcoming are determined. The views of specialists from leading institutions and obstetric and gynecological communities of the world on the issues of pregraved preparation and management of pregnancy in women with HM are presented.
Among the main issues considered are the following: optimal timing for the next pregnancy; key recommendations on the management of women with HM (genetic examination, routine administration of progesterone preparations, correction of the «male factor», psychoemotional disorders, anatomical defects of female reproductive organs); the management of women with reproductive losses in the history on the background of antiphospholipid syndrome and congenital thrombophilia.
It was noted the need to correct the infectious component of miscarriage.
The role of vitamin and micronutrient supplementation in women with HM and their required quantity at the stage of pregravid preparation (folates, iron, iodine, vitamins D, B12) is defined. The evidence base on the use of sublingual and vaginal forms of micronized progesterone (luteina) for correction of the II phase of MC and early pregnancy in women with HM is presented.
The emphasis is also on what should be avoided: unreasonable and unjustified prescriptions without special indications (additional examinations, medications, etc.).
Key words: habitual miscarriage, pregravid preparation, key recommendations, micronutrient supplementation, micronized progesterone, gestalider, luteina.

REFERENCES

1. Antipkin YuG, Davyidova YuV. 2012. Osnovnyie napravleniya razvitiya perinatalnoy meditsinyi. Reproduktiv. endokrinologiya 2:5–7.

2. Holianovskyi OV, Rubinshtein AM, Bachynska MA. 2016. Efektyvnist kombinovanoho zastosuvannia sublinhvalnoi ta vahinalnoi form mikronizovanoho prohesteronu v terapii zahrozy peredchasnykh polohiv. Reprodukt. endokrynolohiia 1:41–46.

3. Goncharov NP. 2002. Kortikosteroidy: metabolizm, mehanizm deystviya i klinicheskoe proyavlenie. M, Adamant:180.

4. Hopchuk OM. 2016. Dyferentsiiovanyi pidkhid do zastosuvannia prohesteronu v akushersko-hinekolohichnii praktytsi. Zdorove zhenshchynу 2:36–41.

5. Dikke G. 2014. Profilaktika poteri beremennosti i prezhdevremennyih rodov u zhenschin grupp riska. Z turbotoyu pro zhInku 2:28–32.

6. Dubossarskaya YuA, Dubossarskaya ZM. 2016. Primenenie mikronizirovannogo progesterona pri nevyinashivanii beremennosti. Reprodukt. endokrinologiya 4:35–39.

7. Zhuk SI, Shchurevska OD. 2011. Psykholohichni aspekty nevynoshuvannia vahitnosti (ohliad literatury). Neonatolohiia, khirurhiia ta perynatalna medytsyna. Chernivtsi. 1;2:132–136.

8. Mogilevkina IA, Guryanov VG. 2016. Primenenie vaginalnogo progesterona v preduprezhdenii prezhdevremennyih rodov: est li preimuschestva? Zdorove zhenschiny 4:28–36.

9. Наказ МОЗ України від 03.11.2008 р. № 624 «Про внесення змін до наказу МОЗ України від 15 грудня 2003 року». Клінічний протокол «Невиношування вагітності».

10. Oleshko VF. 2017. Profilaktyka akusherskykh ta perynatalnykh uskladnen u vahitnykh z nedostatnistiu obturatsiinoi funktsii shyiky matky. Dys. kand. med. nauk. 14.00.01. K:238.

11. Opryishko VI, Nosivets DS. 2015. Sublingvalnaya forma progesterona: neobhodimost v innovatsiyah ili vyizovyi sovremennoy meditsinyi. Zdorove zhenschinyi 10:37–42.

12. Pregravidarnaya podotovka: klinicheskiy protokol. Avt.-razrab. VE Radzinskiy i dr. M, Redaktsiya zhurnala StatusPraesens. 2016:80.

13. Privyichnoe nevyinashivanie beremennosti: prichinyi, versii kontraversii, lechenie. Pod red. Govarda Dzh. A. Karpa, per. s angl. pod red. VE Radzinskogo. M, GEOTAR-Media. 2017:592.

14. Sidelnikova VM, Suhih GT. 2010. Nevyinashivanie beremennosti: ruk. dlya praktikuyuschih vrachey. M, Med. inform. agentstvo:536.

15. Torchinov AV, Umahanova MM, Doronin GL, Dzhonboboeva GN. 2013. Problemyi poteri beremennosti – diagnostika, vedenie beremennosti, lechenie i prognozy na sovremennom etape razvitiya akusherstva: obzor literatury. Lechaschiy vrach 9:85–91.

16. Homfeyr DYu, Neylson DP, Alfirevich Z i dr. 2010. Kokranovskoe rukovodstvo: beremennost i rodyi. Pod obsch. red. GT Suhih; per. s angl. VI Kandrora, OV Ereminoy. M, Logosfera:440.

17. Shurpyak SA, Zhemela NI. 2014. Rol balansa mikroelementov i vitaminov v obespechenii gestatsionnogo protsessa. Zdorove zhenschinyi 5:37–40.

18. Alexander G. 2007. Prematurity at birth: determinants, consequences and geographic variation. National Academies Press. W.: 607–608. Anum EA, Springel EH et al. 2009. Genetic contributions to disparities in preterm birth. Pediatr. Res. 65;1:1–9.

19. Boots CE, Bernardi LA, Stephenson MD. 2014. Frequency of euploid miscarriage is increased in obese women with recurrent early pregnancy loss. Fertility and Sterility. 102;2:455–459. https://doi.org/10.1016/j.fertnstert.2014.05.005; PMid:24907916

20. Da Fonseca EB, Bittar RE, Carvalho MH et al. 2003. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am. J. Obstet. Gynecol. 188;2:419–424. https://doi.org/10.1067/mob.2003.41

21. O’Brien JM, Adair CD, Lewis DF, Hall DR et al. 2007. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 30(5):687–696. https://doi.org/10.1002/uog.5158; PMid:17899572

22. Schindler АE, Carp H, Druckmann R, Genazzani AR et al. 2015. Rekomendatsii Evropeyskogo kluba progestinov po profilaktike i lecheniyu gestagenami ugrozhayuschego ili privyichnogo nevyinashivaniya beremennosti. Zdorove zhenschiny 6:29–31.